Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)

Fig. 2

Amyloid PET analysis. Analysis of the florbetapir change from baseline using three different methods for the calculation of SUVR: in the cerebellar gray MNI-CB (a,d), BAI-WM (b,e), and MNI-WM (c,f). The primary difference between these methods is the choice of reference region: cerebellar gray matter (SUVRMNI-CB) or subcortical white matter (SUVRMNI-WM and SUVRBAI-WM). The reference regions in both the low-dose SC (a–c) and high-dose IV (d–f) cohorts are shown. BAI Banner Alzheimer’s Institute, BL baseline, Cr crenezumab, Diff difference, IV intravenous, MNI molecular neuroimaging, Pl placebo, SC subcutaneous, SE standard error, SUVR standard uptake value ratio, WM white matter, CB cerebellar

Back to article page